The prostate is a small gland in the pelvis and is part of the male reproductive system. Prostate cancer begins when cells in the prostate gland start to grow out of control. In the UK, 1 in 8 men will get prostate cancer in their lifetime with risks increasing due to ethnicity and age.
According to an article in Destinyconnect, research indicates that men with African ancestry or men with darker skin pigmentation globally are twice as likely to contract prostate cancer, and in addition present more aggressive disease characteristics.
A blood test, called a prostate-specific antigen (PSA) test, measures the level of PSA and may help detect early prostate cancer.
DirectorsTalk caught up with Goodbody Health Inc (AQSE:GDBY) CEO Marc Howells to ask the importance of this test:
“Currently there is no screening programme for prostate cancer in the UK. There is an informed choice programme for healthy men aged over 50 who ask their GP about PSA testing. This programme aims to give good information on the pro’s and con’s of a PSA test.
Individuals who have previously been diagnosed with prostate cancer and want to monitor their PSA levels can also access the test. With so many different forms of prostate cancer, we offer the test to any man who wants to check they do not have any form of prostrate cancer that may be identified, as early detection could be a life saver”.
Goodbody Health Group Inc. is listed on the Canadian Securities Exchange (CSE), the Aquis Stock Exchange – Growth Market (AQSE) Apex segment, OTC Pink, and Frankfurt Stock Exchange (FSE), providing current and prospective shareholders with multiple platforms in which to buy and sell Goodbody Health Group Inc. stock under the EPIC codes: CSE: GDBY / AQSE: GDBY / FRA: 484 / OTC: SCNNF. Retail customers can trade via online brokers AJ Bell, Jarvis Investment Management, Interactive Investor and The Share Centre, alongside the extensive range of telephone broking service providers.